Latest news with #BlueprintMedicinesCorp
Mint
4 days ago
- Business
- Mint
French pharma giant Sanofi to buy Biotech Blueprint for $9.1 billion
French pharmaceuticals giant Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's reach in rare immunological diseases, reported the news agency Bloomberg on Monday, 2 June 2025. According to the agency report, Sanofi will pay $129 per share in cash for the US-based biotechnology firm. This marks a 27 per cent premium to Blueprint's shares last week. Blueprint Medicines Corp. shares were trading 26.41 per cent higher at $128.15 premarket on Nasdaq, compared to $101.35 at the previous US market close, as per data collected from Marketwatch. The French pharmaceutical firm aims to become an immunology powerhouse. Blueprint's acquisition brings a pipeline of experimental immunology treatments and one medicine already on sale for a rare condition known as systemic mastocytosis. 'Sanofi still retains a sizable capacity for further acquisitions,' said Paul Hudson, Chief Executive Officer (CEO) of Sanofi, as cited by the news agency. In the big pharma industry, the largest acquisition deal was that of Johnson & Johnson acquiring Intra-Cellular Therapies for $14.6 billion. And this upcoming $9.1 billion deal is the French company's largest deal since the purchase of Bioverativ Inc., a spinoff from Biogen Inc. in 2018, as per the report. 'We see synergies with Sanofi's existing rare-disease footprint, but expect investors to question valuation and confidence in the remaining internal R&D offering,' Sarita Kapila at Morgan Stanley wrote in an analyst report, cited the news agency. Sanofi SA shares were trading 1.46 per cent lower at 86.24 euro on Monday, 2 June 2025, compared to its 87.52 euro levels at the previous market close last week. The deal data suggests that Blueprint shareholders will also receive one non-tradable contingent value right, which will pay the holder @2 and $4 per right for future development and regulatory milestones. The equity value is $9.1 billion, which includes potential CVR payments; the deal amounts to nearly $9.5 billion on a fully diluted basis, according to the agency report. The estimated time period for the completion of the acquisition is the third quarter of 2025. The company also announced that the acquisition deal will not have any impact on the financial guidance for 2025, as per the report.
Yahoo
14-02-2025
- Business
- Yahoo
Blueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...
Total Revenue: $479 million in 2024 from net product sales of AYVAKIT, representing 135% annual growth. AYVAKIT Revenue: Fourth quarter revenue was $144 million, with $124 million in the US and $20 million ex-US. 2025 Revenue Guidance for AYVAKIT: Expected to achieve $680 million to $710 million, representing a 45% increase at the midpoint. Cash Position: Entered 2025 with $864 million in cash. Operating Cash Burn: Reduced by more than 5% in 2024, with further decline expected in 2025. Operating Expenses: Reduced in 2024 compared to 2023, with a modest increase anticipated in 2025 for R&D and SG&A. SM Market Opportunity: Projected peak value of $4 billion, with AYVAKIT as the anchor. Warning! GuruFocus has detected 7 Warning Signs with BPMC. Release Date: February 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Blueprint Medicines Corp (NASDAQ:BPMC) reported a significant annual growth of 135% in product revenue for AYVAKIT, reaching $479 million in 2024. The company projects AYVAKIT revenue to grow to $680 million to $710 million in 2025, with a 45% growth rate at the midpoint. Blueprint Medicines Corp (NASDAQ:BPMC) has penetrated less than 10% of the existing pool of diagnosed systemic mastocytosis (SM) patients, indicating substantial growth potential. The company is expanding its commercial and medical field infrastructure to drive multi-dimensional growth and reach more providers and patients. Blueprint Medicines Corp (NASDAQ:BPMC) has reduced its operating cash burn significantly, demonstrating financial discipline and efficient business operations. The company faces potential financial headwinds in Q1 2025 due to insurance re-verification processes and FX headwinds. Despite the growth, only a fraction of diagnosed SM patients are currently being treated with AYVAKIT, indicating challenges in market penetration. The company anticipates a modest increase in R&D and SG&A expenses in 2025, which could impact profitability. There is uncertainty regarding the timing of international market expansions and reimbursement agreements, which could affect revenue projections. The competitive landscape for AYVAKIT includes symptom-directed therapies, which may pose challenges in achieving the projected $2 billion revenue by 2030. Q: The guidance suggests adding $215 million in AYVAKIT sales this year, but to reach $2 billion by 2030, you'll need to increase annual sales additions. What is the most important lever to achieve this? A: Kathryn Haviland, CEO, emphasized the strong growth trajectory for AYVAKIT, noting that the company is building a solid foundation with experienced prescribers. Christina Rossi, COO, added that expanding the commercial field infrastructure will support growth into 2026 and beyond, enabling the company to reach more diagnosed ISM patients. Q: After reporting BLU-808 data in healthy volunteers, how do you view the safety profile and potential dosing strategies for different indications? A: Lemuel Hewes, CMO, highlighted the wide therapeutic index of BLU-808, allowing for multiple dosing strategies. The company plans to explore these strategies in chronic urticaria and other indications, with initial data expected later this year. Q: How much of the expected growth in 2025 is driven by existing patients versus new patients for AYVAKIT? A: Philina Lee, CCO, noted significant potential for growth from both existing and new prescribers. The company expects to see increased adoption across various specialties, with positive first experiences leading to more patients being treated over time. Q: What assumptions are built into the $2 billion guidance for AYVAKIT, and do you expect any competitor entries? A: Christina Rossi, COO, stated that the guidance considers significant headroom for growth, with the most significant competition being symptom-directed therapy. The company is confident in achieving the $2 billion target through steady growth in patient treatment. Q: Can you provide more details on the field team expansion and its impact on reaching more patients? A: Philina Lee, CCO, explained that the field team expansion will enable more frequent engagements with existing providers and broaden reach to medical dermatologists and gastroenterologists. This expansion is expected to increase penetration among diagnosed SM patients and drive market growth. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
